<DOC>
	<DOCNO>NCT02130765</DOCNO>
	<brief_summary>To demonstrate scar-based ventricular tachycardia ( VT ) ablation use FlexAbility™ ablation catheter system result superior clinical outcome compare routine drug therapy subject document Monomorphic Ventricular Tachycardia [ MMVT ] ( ischemic non-ischemic ) maintain acceptable safety profile .</brief_summary>
	<brief_title>Substrate Targeted Ablation Using FlexAbility™ Ablation Catheter System Reduction Ventricular Tachycardia</brief_title>
	<detailed_description>Approximately 50 center United States ( US ) participate study . Additional center outside US may consider , necessary . The anticipated enrollment duration 48-60 month .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Patient receive new St.Jude Medical ( SJM ) Implantable Cardioverter Defibrillator ( ICD ) SJM Cardiac Resynchronization TherapyDefibrillator ( CRTD ) implant , study require program capability appropriate remote monitoring . Subjects receive ICD / CRTD 90 day prior enrollment also eligible . Patient high risk ICD shock show least one documented Monomorphic VT ( MMVT ) ** one following : Spontaneous MMVT Inducible MMVT electrophysiology ( EP ) Study Inducible MMVT NonInvasive Programmed Stimulation ( NIPS ) Study 18 75 year age Patient inform nature study agree provision provide write informed consent approve Institutional Review Board . Note Pleiomorphic ventricular tachycardia ( VT ) ( multiple MMVT morphology ) acceptable polymorphic VT ventricular fibrillation ( VF ) . Any history stroke ST elevation myocardial infarction ( MI ) previous cardiac surgery within 60 day prior enrollment Patient pregnant nursing Patient New York Heart Association ( NYHA ) class IV heart failure Patient incessant ventricular tachycardia ( VT ) necessitate immediate treatment ( Patients Incessant VT continuous sustain VTs recur promptly despite repeat intervention termination several ( ≥3 ) hour ) Patient VT/VF think channelopathies Limited life expectancy ( less one year ) accord Investigator Patient current class IV angina Recent coronary artery bypass graft ( CABG &lt; 60 day ) percutaneous coronary intervention ( PCI &lt; 30 day ) Patient currently participate another investigational drug device study Patient unable unwilling cooperate study procedure Known presence intracardiac thrombus ( i.e. , positive Transesophageal Echocardiogram ( TEE ) LA LV clot ) . TEE required history leave atrium ( LA ) leave ventricle ( LV ) clot recommend history atrial fibrillation ( AF ) CHADS &gt; 1 Prosthetic mitral aortic valve Mitral aortic valvular heart disease require immediate surgical intervention Major contraindication anticoagulation therapy coagulation disorder Left Ventricular Ejection Fraction &lt; 15 % Patient previous ablation procedure ventricular tachycardia ( VT ) , exclude remote ( &gt; 3 month ) outflow tract tachycardia Patient glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73m2 within past 3 month Patient peripheral vascular disease precludes LV access Patient premature ventricular contraction ( PVC ) VT induce cardiomyopathy expect resolve ablation require ICD Patient reversible cause VT Use leave ventricular assist device ( LVAD ) Tandem Heart device ( Impella Balloon pump acceptable ) There strong clinical reason believe , opinion investigator , patient septal scar deep</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Monomorphic Ventricular Tachycardia</keyword>
	<keyword>Ischemic</keyword>
	<keyword>Non-ischemic</keyword>
	<keyword>Catheter Ablation</keyword>
</DOC>